GlassScriptPhysician profile
Samip Rajendra Master
NPI 1477841682
$20,636.70
in general payments reported to CMS, 2019-2025
53 companies · $4,128 in 2025
The $4,128 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $822 · 2020: $246 · 2021: $1,401 · 2022: $1,843 · 2023: $10K · 2024: $2,012 · 2025: $4,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $4,273 · Travel and Lodging: $1,387 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,390.50 |
| Food and Beverage | $4,273.43 |
| Travel and Lodging | $1,386.60 |
| Education | $273.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $3,823.35 | 2023-2024 | Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $3,066.90 | 2019-2025 | Scemblix |
| Janssen Biotech, INC. | $2,638.87 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Beigene USA, INC. | $2,601.17 | 2021-2024 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $1,312.78 | 2019-2025 | Tagrisso, Imfinzi, Calquence |
| Janssen Scientific Affairs, LLC | $1,106.23 | 2021-2023 | Tecvayli |
| Abbvie INC. | $734.96 | 2020-2025 | |
| Daiichi Sankyo INC. | $642.29 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Beigene, LTD. | $525.00 | 2021 | |
| Astellas Pharma US INC | $395.14 | 2019-2024 | Xospata |
| Celgene Corporation | $358.40 | 2021-2024 | Pomalyst, Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $300.64 | 2019-2025 | Opdivo, Opdualag |
| Seagen INC. | $284.32 | 2021-2025 | Adcetris |
| Kite Pharma, INC. | $282.54 | 2020-2022 | |
| Genentech USA, INC. | $277.11 | 2019-2025 | Tecentriq, Phesgo, Polivy |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samip Master listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.